Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by United Therapeutics Corporation

< Previous 1 2 Next >
United Therapeutics to Acquire Miromatrix Medical
From United Therapeutics Corporation
Via Business Wire
Tickers MIRO UTHR
United Therapeutics Corporation to Report Third Quarter 2023 Financial Results Before the Market Opens on Wednesday, November 1, 2023
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation Reports Second Quarter 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation to Report Second Quarter 2023 Financial Results Before the Market Opens on Wednesday, August 2, 2023
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Unveils Net Zero Energy Distribution Center
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation Reports First Quarter 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at Upcoming Scientific Meetings
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2023
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation Reports Third Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation to Present at the Credit Suisse 31st Annual Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation to Report Third Quarter 2022 Financial Results Before the Market Opens on Wednesday, November 2, 2022
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
From United Therapeutics Corporation
Via Business Wire
Tickers UTHR
United Therapeutics Provides an Update on Its Organ Printing Programs
From United Therapeutics Corporation
Via Business Wire
Tickers DDD UTHR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.